A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies

B Hill, D Jagadeesh, B Pohlman, R Dean… - Seminars in …, 2021 - Elsevier
One mechanism by which lymphoid malignancies resist standard apoptosis-intending
(cytotoxic) treatments is genetic attenuation of the p53/p16-CDKN2A apoptosis axis …
被引用次数：8 相关文章

A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies

B Hill, D Jagadeesh, B Pohlman… - Seminars in …, 2021 - pubmed.ncbi.nlm.nih.gov
One mechanism by which lymphoid malignancies resist standard apoptosis-intending
(cytotoxic) treatments is genetic attenuation of the p53/p16-CDKN2A apoptosis axis …

A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.

B Hill, D Jagadeesh, B Pohlman, R Dean… - Seminars in …, 2020 - europepmc.org
One mechanism by which lymphoid malignancies resist standard apoptosis-intending
(cytotoxic) treatments is genetic attenuation of the p53/p16-CDKN2A apoptosis axis …
[HTML] nih.gov

[HTML][HTML] A Pilot Clinical Trial of Oral Tetrahydrouridine/Decitabine for Non-Cytotoxic Epigenetic Therapy of Chemo-resistant Lymphoid Malignancies

B Hill, D Jagadeesh, B Pohlman, R Dean… - Seminars in …, 2021 - ncbi.nlm.nih.gov
One mechanism by which lymphoid malignancies resist standard apoptosis-intending
(cytotoxic) treatments is genetic attenuation of the p53/p16-CDKN2A apoptosis axis …